(Press-News.org) SAN DIEGO – A new drug may improve memory problems in people with moderate Alzheimer's disease, according to a phase IIa study released today that will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013. The drug is called ORM-12741.
The drug is the first to target a specific subtype of adrenergic receptors (alpha-2C) in the brain, which are believed to be involved in modulation of brain functions under stressful conditions, or the "fight or flight" response. For the clinical trial, 100 people with moderate Alzheimer's disease were randomly given either 30 to 60 milligrams or 100 to 200 milligrams of ORM-12741 or matching placebo pill twice a day for three months as add-on therapy to a cholinesterase drug. Additionally, use of memantine was allowed. These are the other Alzheimer drugs currently on the market. Neither the researchers nor the participants knew which treatments participants were receiving.
After three months, researchers retested several aspects of the participants' memory and behavior. Those who took ORM-12741 tested higher on the tests of memory compared to those who received the placebo pill. At three months, the memory scores for those who received the placebo pill had worsened by 33 percent, whereas the scores improved by 4 percent for those who took ORM-12741.
"Currently, there are still only a handful of Alzheimer's drugs on the market and they have only moderate effects on the symptoms of the disease," said study author Juha Rouru, MD, of Orion Pharma in Turku, Finland. "Anytime you have a drug that targets a new pathway in the brain and shows effectiveness in clinical trials, it is exciting."
It is estimated that 13.8 million people will have Alzheimer's disease by 2050.
###
The study was supported by Orion Pharma.
Learn more about Alzheimer's disease at http://www.aan.com/patients.
The American Academy of Neurology, an association of more than 25,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer's disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson's disease and epilepsy.
For more information about the American Academy of Neurology, visit http://www.aan.com or find us on Facebook, Twitter, Google+ and YouTube
Media Contacts:
Rachel Seroka, rseroka@aan.com, (612) 928-6129
Angela Babb, APR, ababb@aan.com, (612) 928-6102
New add-on drug may improve memory in people with moderate Alzheimer's disease
2013-03-12
ELSE PRESS RELEASES FROM THIS DATE:
Global consensus on concussion in sport
2013-03-12
An international panel of concussion experts has provided new guidelines on evaluating and treating concussions during sporting events and in clinical settings.
Dr. Willem Meeuwisse, a physician, researcher and leader of the University of Calgary Brain Injury Initiative with the Hotchkiss Brain Institute (HBI), Alberta Children's Hospital Research Institute (ACHRI) and the Faculties of Kinesiology and Medicine, co-chaired an expert panel and co-authored the document entitled "The Consensus Statement on Concussion in Sport; the 4th International Conference on Concussion ...
Men in same-sex marriages are living longer, according to new study
2013-03-12
The mortality rate for men in same-sex marriages has dropped markedly since the 1990s, according to a Danish study published online today (Tuesday) in the International Journal of Epidemiology. However, same-sex married women have emerged as the group of women with the highest, and in recent years, even further increasing mortality.
Denmark implemented the world's first national law on registered same-sex partnerships in 1989. Mortality was markedly elevated among people in same-sex marriages for the first several years after this, but since 1996, with the advent of effective ...
Sildenafil for heart failure does not result in significant improvement in exercise capacity
2013-03-12
Among patients with heart failure with preserved ejection fraction (a measure of heart function), administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status, according to a study published online by JAMA. Some studies have suggested that phosphodiesterase-5 inhibitors (a class of drugs that includes sildenafil) may improve cardiovascular function. The study is being released early to coincide with its presentation at the American College of Cardiology's annual Scientific Sessions.
Heart ...
Combination therapy for heart failure does not reduce risk of CV death or rehospitalization
2013-03-12
Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA. The study is being released early to coincide with its presentation at the American College of Cardiology's annual Scientific Sessions.
"Inhibition of the renin-angiotensin-aldosterone ...
Kids exposed to millions of tobacco images/messages every week on prime time UK TV
2013-03-12
UK children are being exposed to millions of tobacco images/messages every week on prime time television, indicates research published online in Tobacco Control.
Smoking and other tobacco content frequently feature in films marketed to kids, which is known to spark their interest in starting to smoke, say the authors.
More stringent curbs on tobacco imagery in the TV programme schedule could help curb uptake among young people, who spend an average of 2.5 hours in front of the box every day, they suggest.
The authors analysed the weekly content of all five free to ...
Sleep loss precedes Alzheimer's symptoms
2013-03-12
Sleep is disrupted in people who likely have early Alzheimer's disease but do not yet have the memory loss or other cognitive problems characteristic of full-blown disease, researchers at Washington University School of Medicine in St. Louis report March 11 in JAMA Neurology.
The finding confirms earlier observations by some of the same researchers. Those studies showed a link in mice between sleep loss and brain plaques, a hallmark of Alzheimer's disease. Early evidence tentatively suggests the connection may work in both directions: Alzheimer's plaques disrupt sleep, ...
No good evidence that mouthguards and helmets ward off concussion
2013-03-12
Mouthguards and helmets can help ward off other serious head and facial injuries, but there is no good evidence that they can help prevent concussion, and paradoxically, they may even encourage players to take greater risks.
But that is precisely why it is so important to recognise and treat concussive symptoms promptly, says the Consensus Statement on Concussion in Sport, published in the British Journal of Sports Medicine.
The Consensus Statement is the fourth revision of recommendations first developed in 2001 in Vienna, in a bid to offer some practical and evidence ...
Protected areas successfully prevent deforestation in Amazon rainforest
2013-03-12
ANN ARBOR — Strictly protected areas such as national parks and biological reserves have been more effective at reducing deforestation in the Amazon rainforest than so-called sustainable-use areas that allow for controlled resource extraction, two University of Michigan researchers and their colleagues have found.
In addition, protected areas established primarily to safeguard the rights and livelihoods of indigenous people performed especially well in places where deforestation pressures are high. The U-M-led study, which found that all forms of protection successfully ...
Hope for threatened Tasmanian devils
2013-03-12
New research paves the way for the development of a vaccine for the Tasmanian devil, currently on the brink of extinction because of a contagious cancer.
It has been less than two decades since scientists discovered the contagious cancer devil facial tumour disease (DFTD) which causes 100 per cent mortality in the endangered marsupials. The facial cancer, which spreads when the devils bite each other's faces during fighting, kills its victims in a matter of months. As it has already wiped out the majority of the population with sightings of devils reduced by 85 per cent, ...
New checklist brings information about Cucurbitaceae up to date
2013-03-12
In 2010, it was shown that melons and cucumbers can be traced back to India. Because of the importance of the region for an understanding of Cucurbitaceae evolution and diversity, a new checklist of the Cucurbitaceae of India was produced to update the information on that family. The study was published in the open access journal PhytoKeys.
Vegetables are essential components of a healthy daily diet, not just in India but around the globe. Compared to grains and pulses, however, vegetables are under-investigated taxonomically, and information on their genome is scarce. ...